Leaflet immobility and thrombosis in transcatheter aortic valve replacement

Arnold C.T. Ng, David R. Holmes, Michael J. Mack, Victoria Delgado, Raj Makkar, Philipp Blanke, Jonathon A. Leipsic, Martin B. Leon, Jeroen J. Bax

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Transcatheter aortic valve replacement (TAVR) has grown exponentially worldwide in the last decade. Due to the higher bleeding risks associated with oral anticoagulation and in patients undergoing TAVR, antiplatelet therapy is currently considered first-line antithrombotic treatment after TAVR. Recent studies suggest that some patients can develop subclinical transcatheter heart valve (THV) thrombosis after the procedure, whereby thrombus forms on the leaflets that can be a precursor to leaflet dysfunction. Compared with echocardiography, multidetector computed tomography is more sensitive at detecting THV thrombosis. Transcatheter heart valve thrombosis can occur while on dual antiplatelet therapy with aspirin and thienopyridine but significantly less with anticoagulation. This review summarizes the incidence and diagnostic criteria for THV thrombosis and discusses the pathophysiological mechanisms that may lead to thrombus formation, its natural history, potential clinical implications and treatment for these patients.

Original languageEnglish (US)
Pages (from-to)3184-3197
Number of pages14
JournalEuropean heart journal
Issue number33
StatePublished - Sep 1 2020


  • Antiplatelet therapy
  • Antithrombotic treatment
  • Thrombosis
  • Transcatheter aortic valve replacement
  • Transcatheter heart valve

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Leaflet immobility and thrombosis in transcatheter aortic valve replacement'. Together they form a unique fingerprint.

Cite this